The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

Karimi, Narges; Razian, Azadeh; Heidari, Mohammad

doi:10.1007/s13760-019-01101-x

Cited by 20 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…provides evidence that intravenous magnesium has a modest beneficial effect on acute migraine attacks and that oral magnesium reduces attack frequency and intensity 188 . A randomized controlled trial published in 2019 showed that 500 mg magnesium oxide daily had a similar preventive effect in migraine as 400 mg sodium valproate daily 189 .…”

Section: Prophylactic Nutraceuticalsmentioning

confidence: 99%

The metabolic face of migraine — from pathophysiology to treatment

et al. 2019

View full text Add to dashboard Cite

Migraine can be regarded as a conserved, adaptive response that occurs in genetically predisposed individuals with a mismatch between the brain's energy reserve and workload. Given the high prevalence of migraine, genotypes associated with the condition seem likely to have conferred an evolutionary advantage. Technological advances have enabled the examination of different aspects of cerebral metabolism in patients with migraine, and complementary animal research has highlighted possible metabolic mechanisms in migraine pathophysiology. An increasing amount of evidence-much of it clinical-suggests that migraine is a response to cerebral energy deficiency or oxidative stress levels that exceed antioxidant capacity and that the attack itself helps to restore brain energy homeostasis and reduces harmful oxidative stress levels. Greater understanding of metabolism in migraine offers novel therapeutic opportunities. In this Review , we describe the evidence for abnormalities in energy metabolism and mitochondrial function in migraine, with a focus on clinical data (including neuroimaging, biochemical, genetic and therapeutic studies), and consider the relationship of these abnormalities with the abnormal sensory processing and cerebral hyper-responsivity observed in migraine. We discuss experimental data to consider potential mechanisms by which metabolic abnormalities could generate attacks. Finally , we highlight potential treatments that target cerebral metabolism, such as nutraceuticals, ketone bodies and dietary interventions.

show abstract

Section: Prophylactic Nutraceuticalsmentioning

confidence: 99%

The metabolic face of migraine — from pathophysiology to treatment

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We observed that most people had good effect with the lowest dose, and reuse of valproic acid is still effective for recurrence of vertigo. In addition, different types of medications have been typically used in VM prophylaxis including anticonvulsants (topiramate), calcium antagonists (flunarizine), β-blockers (propranolol and metoprolol), and antidepressants (amitriptyline and venlafaxine) (16,(19)(20)(21). In our earlier study, we found that most drugs (calcium antagonists, β-blockers and antidepressants) had no significant effect in treating pseudo-BPPV.…”

Section: Discussionmentioning

confidence: 96%

“…Valproic acid, also known as sodium valproateis, is the first-line clinical treatment of systemic and partial seizure epilepsy (14) and absence seizures in children and adolescents (15). It is also administered for the treatment of migraine headaches (16). The main mechanism of valproic acid may be related to indirectly regulating neurotransmitter release through the regulation of ionic currents and facilitating GABAergic over glutamatergic transmission (14).…”

Section: Discussionmentioning

confidence: 99%

Pseudo-Benign Paroxysmal Positional Vertigo: A Retrospective Study and Case Report

Guan

et al. 2020

Front. Neurol.

View full text Add to dashboard Cite

Pseudo-benign paroxysmal positional vertigo (pseudo-BPPV) is a specific type of vestibular migraine disguised as benign paroxysmal positional vertigo, which is characterized by recurrent different types of positional and atypical positional vertigo with migraine features. It is easy to be misdiagnosed with BPPV at the first visit, which means that the ideal therapeutic effects are not achieved. Twenty-five cases of pseudo-BPPV with frequent changing positional vertigo were retrospected and the following key features help to identify the disease: recurrent positional and atypical positional vertigo, migrainous accompanying symptoms or migraine history, mild or indistinctive headaches, with or without impaired vestibular function, ineffective for simply reposition. And we found that vertigo in pseudo-BPPV can be preferable controlled by valproic acid combined with canalith repositioning procedure.

show abstract

“…Karimi and colleagues, in a randomized, double-blind, controlled, crossover trial, gave 63 patients oral daily 500 mg magnesium oxide followed by 800 mg valproate sodium (400 mg every 12 h) or vice versa for 24 weeks. Patients showed a similar number and mean duration of migraine attacks in both groups, indicating that magnesium oxide is as effective as valproate in migraine prophylaxis without significant adverse effects [ 70 ].…”

Section: Magnesium Supplementation—therapeutic Efficacymentioning

confidence: 99%

“…Side effects were not measured in all studies, but in those that were, diarrhoea and gastric effects were the most common, although mild in all instances, and did not prevent patients from completing treatment [ 32 , 33 , 69 , 70 , 75 ]. See Table 3 for studies describing the efficacy and safety of magnesium in treating headache symptoms.…”

Section: Magnesium Supplementation—therapeutic Efficacymentioning

confidence: 99%

Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate

et al. 2020

View full text Add to dashboard Cite

Magnesium deficiency may occur for several reasons, such as inadequate intake or increased gastrointestinal or renal loss. A large body of literature suggests a relationship between magnesium deficiency and mild and moderate tension-type headaches and migraines. A number of double-blind randomized placebo-controlled trials have shown that magnesium is efficacious in relieving headaches and have led to the recommendation of oral magnesium for headache relief in several national and international guidelines. Among several magnesium salts available to treat magnesium deficiency, magnesium pidolate may have high bioavailability and good penetration at the intracellular level. Here, we discuss the cellular and molecular effects of magnesium deficiency in the brain and the clinical evidence supporting the use of magnesium for the treatment of headaches and migraines.

show abstract

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

Cited by 20 publications

References 25 publications

The metabolic face of migraine — from pathophysiology to treatment

The metabolic face of migraine — from pathophysiology to treatment

Pseudo-Benign Paroxysmal Positional Vertigo: A Retrospective Study and Case Report

Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate

Contact Info

Product

Resources

About